Silverarc Capital Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Silverarc Capital Management, LLC reported 64 stock positions worth $898.5 million. Its top holding was Ascendis Pharma A/S (ASND) at 6.1% of the portfolio, followed by Celcuity (CELC, 5.8%) and Cogent Biosciences (COGT, 5.5%). Compared with Q1 2026, it opened 19 new positions, sold out of 21, added to 17 and reduced 27. The biggest buy was Oruka Therapeutics (ORKA, shares +134%) and the biggest sale an exit from Kalvista Pharmaceuticals (KALV).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001816307
- Portfolio Value
- $898.5M (Q2 2026)
- SEC Filing
- 0001420506-26-001563 ↗ filed Aug 13, 2026
Holdings Value
Holdings 64 stocks · $898.5M
| ASND Ascendis Pharma A/S | 6.12% | 206,234 | $55.0M | Add +65.4% |
| CELC Celcuity Inc. | 5.83% | 500,996 | $52.4M | Add +40.0% |
| COGT Cogent Biosciences Inc. | 5.52% | 1,280,707 | $49.6M | Reduce -2.5% |
| URGN Urogen Pharma Ltd. | 5.33% | 1,301,979 | $47.9M | Reduce -13.4% |
| IMNM Immunome Inc. | 4.76% | 2,017,009 | $42.7M | Add +9.0% |
| DNTH Dianthus Therapeutics Inc. | 4.23% | 390,000 | $38.0M | Reduce -40.4% |
| RYTM Rhythm Pharmaceuticals Inc. | 3.85% | 311,461 | $34.6M | Add +1.8% |
| ORKA Oruka Therapeutics Inc. | 3.74% | 352,802 | $33.6M | Add +133.8% |
| GLUE Monte Rosa Therapeutics Inc. | 2.98% | 1,108,295 | $26.8M | Reduce -44.6% |
| SNDX Syndax Pharmaceuticals Inc. | 2.95% | 1,214,390 | $26.5M | Add +36.6% |
| ELVN Enliven Therapeutics Inc. | 2.76% | 489,382 | $24.8M | New |
| IMVT Immunovant Inc. | 2.65% | 619,096 | $23.9M | Add +49.5% |
| ERAS Erasca Inc. | 2.58% | 1,263,026 | $23.1M | Reduce -31.8% |
| SGMT Sagimet Biosciences Inc. Class A | 2.52% | 2,927,698 | $22.6M | New |
| ABVX Abivax SA-ADR | 2.52% | 169,593 | $22.6M | Reduce -43.9% |
| PRAX Praxis Precision Medicines I | 2.45% | 65,679 | $22.0M | Reduce -8.2% |
| KOD Kodiak Sciences Inc. | 2.37% | 546,256 | $21.3M | Reduce -44.9% |
| DFTX Definium Therapeutics Inc. | 2.09% | 400,000 | $18.8M | New |
| VCYT Veracyte Inc. | 2.08% | 318,001 | $18.7M | Add +77.0% |
| GH Guardant Health Inc. | 1.67% | 99,826 | $15.0M | Add +1.3% |
| CCCC C4 Therapeutics Inc. | 1.58% | 3,032,060 | $14.2M | Add +58.6% |
| ZBIO Zenas Biopharma Inc. | 1.44% | 509,789 | $12.9M | Reduce -55.1% |
| TRVI Trevi Therapeutics Inc. | 1.41% | 678,095 | $12.6M | Add +32.7% |
| HLXC Helix Acquisition Corp. Class A | 1.39% | 1,177,821 | $12.5M | Reduce -2.6% |
| ALXO Alx Oncology Holdings Inc. | 1.32% | 5,744,757 | $11.9M | New |
| MANE Veradermics Inc. | 1.30% | 95,000 | $11.7M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.25% | 186,821 | $11.3M | Reduce -5.5% |
| AVLN Avalyn Pharma Inc. | 1.21% | 330,487 | $10.9M | New |
| BIIB Biogen Inc. | 1.16% | 48,101 | $10.4M | Reduce -5.6% |
| ACRS Aclaris Therapeutics Inc. | 1.15% | 1,946,482 | $10.3M | New |
| CERS Cerus Corp. | 1.13% | 3,472,737 | $10.1M | Add +9.3% |
| AVTX Avalo Therapeutics Inc. | 1.03% | 500,402 | $9.2M | New |
| BNTC Benitec Biopharma Inc. | 1.01% | 679,826 | $9.1M | Reduce -5.3% |
| PCVX Vaxcyte Inc. | 0.94% | 145,000 | $8.4M | Add +0.0% |
| WGS Genedx Holdings Corp. | 0.93% | 122,269 | $8.4M | New |
| SVRA Savara Inc. | 0.93% | 1,355,459 | $8.3M | Reduce -5.3% |
| OVID Ovid Therapeutics Inc. | 0.93% | 3,101,129 | $8.3M | Add +210.1% |
| ORIC Oric Pharmaceuticals Inc. | 0.89% | 738,873 | $8.0M | Reduce -32.8% |
| CMPS Compass Pathways PLC | 0.79% | 503,382 | $7.1M | Add +67.8% |
| CGEN Compugen Ltd. | 0.76% | 3,184,257 | $6.8M | Reduce -4.0% |
| SLDB Solid Biosciences Inc. | 0.74% | 668,450 | $6.7M | New |
| IBIO Ibio Inc. | 0.69% | 3,520,490 | $6.2M | Add +1457.7% |
| IRON Disc Medicine Inc. | 0.67% | 82,800 | $6.1M | Reduce -57.8% |
| ALKS Alkermes PLC | 0.66% | 113,494 | $5.9M | Reduce -75.3% |
| SYRE Spyre Therapeutics Inc. | 0.59% | 59,959 | $5.3M | Reduce -67.9% |
| ARTV Artiva Biotherapeutics Inc. | 0.57% | 525,000 | $5.1M | New |
| CTNM Contineum Therapeutics Inc. Class A | 0.54% | 296,135 | $4.9M | Reduce -1.9% |
| QURE Uniqure NV | 0.54% | 105,000 | $4.8M | New |
| RACC Research Alliance Corp. Class A | 0.43% | 360,000 | $3.9M | New |
| ABEO Abeona Therapeutics Inc. | 0.42% | 610,407 | $3.8M | Reduce -5.9% |
| INSM Insmed Inc. | 0.41% | 34,438 | $3.7M | Reduce -3.9% |
| KPTI Karyopharm Therapeutics Inc. | 0.32% | 297,460 | $2.9M | New |
| CAMP CAMP4 Therapeutics Corp. | 0.32% | 653,594 | $2.9M | No change |
| ELUT Elutia Inc. | 0.24% | 2,192,980 | $2.1M | Reduce -12.2% |
| RVMD Revolution Medicines Inc. | 0.21% | 10,000 | $1.9M | New |
| SION Sionna Therapeutics Inc. | 0.21% | 42,478 | $1.9M | Add +7.8% |
| TELA Tela Bio Inc. | 0.18% | 2,137,201 | $1.6M | Reduce -5.4% |
| ACHV Achieve Life Sciences Inc. | 0.17% | 227,178 | $1.5M | New |
| GUTS Fractyl Health Inc. | 0.14% | 1,637,976 | $1.3M | Reduce -3.7% |
| CNTB Connect Biopharma Holdings L | 0.14% | 545,000 | $1.3M | New |
| CBIO Crescent Biopharma Inc. | 0.12% | 59,104 | $1.1M | Reduce -54.7% |
| CLRB Cellectar Biosciences Inc. | 0.10% | 321,728 | $894K | New |
| FHTX Foghorn Therapeutics Inc. | 0.03% | 45,975 | $224K | New |
| ADGM Adagio Medical Holdings Inc. | 0.02% | 224,360 | $146K | Reduce -11.0% |
Options reported separately and not counted above: ARK ETF TR puts ($21.0M), SYNDAX PHARMACEUTICALS INC calls ($15.2M), ORIC PHARMACEUTICALS INC calls ($7.4M), MONTE ROSA THERAPEUTICS INC calls ($7.3M), ABIVAX SA calls ($6.7M), KYMERA THERAPEUTICS INC puts ($2.9M), ABSCI CORPORATION puts ($1.8M), FULCRUM THERAPEUTICS INC calls ($1.4M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $356 (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 104,828 | $356 | No change |
Total filed on the 13F, all lines: $898.5M.
Portfolio Sells Q1 2026 → Q2 2026
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −6.82 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −4.28 |
| DNTH Dianthus Therapeutics Inc. | Reduce -40.4% | 4.23% | −2.24 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −2.18 |
| KOD Kodiak Sciences Inc. | Reduce -44.9% | 2.37% | −2.09 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −1.97 |
| ABVX Abivax SA-ADR | Reduce -43.9% | 2.52% | −1.45 |
| CGON CG Oncology Inc. | Sold out | 0.00% | −1.33 |
| ALKS Alkermes PLC | Reduce -75.3% | 0.66% | −1.26 |
| ZBIO Zenas Biopharma Inc. | Reduce -55.1% | 1.44% | −1.18 |
| ERAS Erasca Inc. | Reduce -31.8% | 2.58% | −0.96 |
| GLUE Monte Rosa Therapeutics Inc. | Reduce -44.6% | 2.98% | −0.90 |
| IRON Disc Medicine Inc. | Reduce -57.8% | 0.67% | −0.80 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -32.8% | 0.89% | −0.75 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −0.67 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.55 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −0.55 |
| CMPX Compass Therapeutics Inc. | Sold out | 0.00% | −0.54 |
| SYRE Spyre Therapeutics Inc. | Reduce -67.9% | 0.59% | −0.52 |
| SRZN Surrozen Inc. | Sold out | 0.00% | −0.50 |
| COGT Cogent Biosciences Inc. | Reduce -2.5% | 5.52% | −0.44 |
| ZURA Zura Bio Ltd. | Sold out | 0.00% | −0.39 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.38 |
| ANNX Annexon Inc. | Sold out | 0.00% | −0.32 |
| INSM Insmed Inc. | Reduce -3.9% | 0.41% | −0.28 |
| MNPR Monopar Therapeutics Inc. | Sold out | 0.00% | −0.28 |
| PRAX Praxis Precision Medicines I | Reduce -8.2% | 2.45% | −0.27 |
| NXTC Nextcure Inc. | Sold out | 0.00% | −0.22 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −0.19 |
| CBIO Crescent Biopharma Inc. | Reduce -54.7% | 0.12% | −0.16 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −0.15 |
| GENB Generate Biomedicines Inc. | Sold out | 0.00% | −0.15 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -5.5% | 1.25% | −0.10 |
| RADX Radiopharm Theranostics Ltd. | Sold out | 0.00% | −0.10 |
| CGEN Compugen Ltd. | Reduce -4.0% | 0.76% | −0.07 |
| ELUT Elutia Inc. | Reduce -12.2% | 0.24% | −0.07 |
| HLXC Helix Acquisition Corp. Class A | Reduce -2.6% | 1.39% | −0.05 |
| ADGM Adagio Medical Holdings Inc. | Reduce -11.0% | 0.02% | −0.02 |
| AARD Aardvark Therapeutics Inc. | Sold out | 0.00% | −0.01 |
| SVRA Savara Inc. | Reduce -5.3% | 0.93% | +0.01 |
| TELA Tela Bio Inc. | Reduce -5.4% | 0.18% | +0.01 |
| GUTS Fractyl Health Inc. | Reduce -3.7% | 0.14% | +0.05 |
| BIIB Biogen Inc. | Reduce -5.6% | 1.16% | +0.06 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce -1.9% | 0.54% | +0.08 |
| ABEO Abeona Therapeutics Inc. | Reduce -5.9% | 0.42% | +0.08 |
| BNTC Benitec Biopharma Inc. | Reduce -5.3% | 1.01% | +0.11 |
| URGN Urogen Pharma Ltd. | Reduce -13.4% | 5.33% | +2.15 |
Portfolio Buys Q1 2026 → Q2 2026
| ORKA Oruka Therapeutics Inc. | Add +133.8% | 3.74% | +2.86 |
| ELVN Enliven Therapeutics Inc. | New | 2.76% | +2.76 |
| ASND Ascendis Pharma A/S | Add +65.4% | 6.12% | +2.76 |
| SGMT Sagimet Biosciences Inc. Class A | New | 2.52% | +2.52 |
| DFTX Definium Therapeutics Inc. | New | 2.09% | +2.09 |
| IMVT Immunovant Inc. | Add +49.5% | 2.65% | +1.44 |
| VCYT Veracyte Inc. | Add +77.0% | 2.08% | +1.40 |
| ALXO Alx Oncology Holdings Inc. | New | 1.32% | +1.32 |
| MANE Veradermics Inc. | New | 1.30% | +1.30 |
| AVLN Avalyn Pharma Inc. | New | 1.21% | +1.21 |
| ACRS Aclaris Therapeutics Inc. | New | 1.15% | +1.15 |
| AVTX Avalo Therapeutics Inc. | New | 1.03% | +1.03 |
| CELC Celcuity Inc. | Add +40.0% | 5.83% | +1.02 |
| CCCC C4 Therapeutics Inc. | Add +58.6% | 1.58% | +0.98 |
| WGS Genedx Holdings Corp. | New | 0.93% | +0.93 |
| SLDB Solid Biosciences Inc. | New | 0.74% | +0.74 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +1.8% | 3.85% | +0.71 |
| TRVI Trevi Therapeutics Inc. | Add +32.7% | 1.41% | +0.69 |
| OVID Ovid Therapeutics Inc. | Add +210.1% | 0.93% | +0.67 |
| IBIO Ibio Inc. | Add +1457.7% | 0.69% | +0.64 |
| CMPS Compass Pathways PLC | Add +67.8% | 0.79% | +0.60 |
| GH Guardant Health Inc. | Add +1.3% | 1.67% | +0.59 |
| ARTV Artiva Biotherapeutics Inc. | New | 0.57% | +0.57 |
| QURE Uniqure NV | New | 0.54% | +0.54 |
| SNDX Syndax Pharmaceuticals Inc. | Add +36.6% | 2.95% | +0.51 |
| CERS Cerus Corp. | Add +9.3% | 1.13% | +0.45 |
| RACC Research Alliance Corp. Class A | New | 0.43% | +0.43 |
| KPTI Karyopharm Therapeutics Inc. | New | 0.32% | +0.32 |
| RVMD Revolution Medicines Inc. | New | 0.21% | +0.21 |
| ACHV Achieve Life Sciences Inc. | New | 0.17% | +0.17 |
| CNTB Connect Biopharma Holdings L | New | 0.14% | +0.14 |
| CLRB Cellectar Biosciences Inc. | New | 0.10% | +0.10 |
| FHTX Foghorn Therapeutics Inc. | New | 0.03% | +0.03 |
| SION Sionna Therapeutics Inc. | Add +7.8% | 0.21% | +0.02 |
| IMNM Immunome Inc. | Add +9.0% | 4.76% | −0.01 |
| PCVX Vaxcyte Inc. | Add +0.0% | 0.94% | −0.05 |
Options Activity Q1 2026 → Q2 2026
| SPDR SERIES TRUST | put | Sold out | 825,000 | $105.4Mbefore exit |
| ARK ETF TR | put | New | 500,000 | $21.0M |
| SYNDAX PHARMACEUTICALS INC | call | Add +116.8% | 693,600 | $15.2M |
| UNIQURE NV | call | Sold out | 500,000 | $8.2Mbefore exit |
| ORIC PHARMACEUTICALS INC | call | New | 682,600 | $7.4M |
| MONTE ROSA THERAPEUTICS INC | call | New | 300,000 | $7.3M |
| ABIVAX SA | call | New | 50,000 | $6.7M |
| CELCUITY INC | call | Sold out | 54,500 | $6.2Mbefore exit |
| KYMERA THERAPEUTICS INC | put | New | 25,000 | $2.9M |
| ABSCI CORPORATION | put | New | 157,600 | $1.8M |
| COMPASS THERAPEUTICS INC | call | Sold out | 172,400 | $912Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 64 | $898.5M | ASND, CELC, COGT, URGN, IMNM |
| Q1 2026 | 66 | $848.6M | KALV, DNTH, COGT, CELC, IMNM |
| Q4 2025 | 63 | $691.1M | ABVX, COGT, URGN, KALV, CELC |
| Q3 2025 | 72 | $690.7M | ABVX, RYTM, RNAM, NUVL, URGN |
| Q2 2025 | 56 | $488.6M | MRUS, AKRO, VRNA, URGN, RYTM |
| Q1 2025 | 66 | $478.6M | VRNA, MRUS, NUVL, AKRO, INSM |
| Q4 2024 | 57 | $447.2M | NUVL, MRUS, INSM, VRNA, AKRO |
| Q3 2024 | 67 | $443.7M | NUVL, MRUS, INSM, RNAM, ERAS |
| Q2 2024 | 65 | $405.1M | MRUS, NUVL, RNAM, URGN, ERAS |
| Q1 2024 | 72 | $356.6M | MRUS, SLDB, MORF, ORIC, MERSANA THERAPEUTICS INC |